BioCentury
ARTICLE | Company News

Antisoma, Merck KGaA deal

August 2, 2004 7:00 AM UTC

ASM acquired from partner EMD Lexigen Research Center (Billerica, Mass.), a subsidiary of MRK, exclusive rights to BC1-IL12, a preclinical compound that ASM has renamed AS1409. AS1409 links ASM's huBC...